Comorbidity among Danish lung cancer patients before and after initial cancer diagnosis
| Autor: | Ole Hilberg, Torben Riis Rasmussen, Anja Gouliaev, Anders Løkke, Rikke Ibsen, Niels Lyhne Christensen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Longitudinal study medicine.medical_specialty case-control study Population Diseases of the respiratory system 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine Lung cancer education Survival rate Survival analysis education.field_of_study RC705-779 business.industry Case-control study Cancer medicine.disease mortality Comorbidity lung cancer comorbidity 030228 respiratory system business Research Article |
| Zdroj: | Gouliaev, A, Hilberg, O, Christensen, N L, Rasmussen, T, Ibsen, R & Løkke, A 2021, ' Comorbidity among Danish lung cancer patients before and after initial cancer diagnosis ', European Clinical Respiratory Journal, vol. 8, no. 1, 1861579 . https://doi.org/10.1080/20018525.2020.1861579 European Clinical Respiratory Journal, Vol 8, Iss 1 (2021) European Clinical Respiratory Journal article-version (VoR) Version of Record |
| ISSN: | 2001-8525 |
| DOI: | 10.1080/20018525.2020.1861579 |
| Popis: | Objective: Lung cancer is the leading cause of cancer-related death worldwide. This population-based longitudinal study investigates survival rates and the burden of comorbidity before and after being diagnosed with lung cancer in Denmark. Methods: From the Danish National Patient Registry (NPR) and the Danish Civil Registration System (CPR), 53,749 patients with lung cancer were identified and matched with 214,304 controls on age, gender, region of residence and marital status in the period 1998–2010. From the NPR, data on survival and comorbidity, registered as ICD-10 diagnoses, were extracted. Comorbidity was assessed using the Deyo-Charlson comorbidity score (DCcs) and mortality using Kaplan-Meier survival curves. Results: 1-year survival rate for Danish lung cancer patients was 51.7 % (CI 51.3-52.1) and 5-year survival rate was 14.7 % (CI 14.3-15.0) compared to 96.8 % (CI 96.7-96.8) and 84.0 % (CI 83.9-84.2) for controls respectively. Overall, cases had significantly more comorbidity compared to controls before being diagnosed with lung cancer. Prior to being diagnosed with lung cancer, more cases than controls had been diagnosed with other malignancies (11.4 % vs 6.0 % p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|